Hypothesis: Metabolic syndrome modulation through GLP-1 receptor agonist therapy will improve metabolic parameters, reduce neuroinflammation, and slow disease progression in Parkinson's disease patients with metabolic dysfunction.
- Sample Size: 200 participants (100 treatment, 100 placebo)
- Inclusion Criteria:
- Age 50-75 years
- PD diagnosis (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Disease duration 1-8 years
- Evidence of metabolic dysfunction (≥2 of: BMI ≥28, HbA1c 5.7-6.9%, triglycerides >150 mg/dL, HDL <40 mg/dL men/<50 mg/dL women, BP >130/85 mmHg)
- Stable dopaminergic therapy for ≥1 month
- Exclusion Criteria:
- Type 1 or Type 2 diabetes on insulin therapy
- History of pancreatitis
- Current GLP-1 agonist use
- Severe renal or hepatic impairment
- Active cancer
- Treatment Arm: Liraglutide 1.8 mg daily (titrated over 4 weeks)
- Subcutaneous injection
- Standard diabetes dosing for neuroprotection
- Placebo Arm: Matching placebo injection
- 12-month treatment period
- 6-month follow-up off intervention
- Change in MDS-UPDRS Part III (motor score) at 12 months
- Change in HbA1c at 12 months (confirm metabolic improvement)
- Neuroinflammatory markers (IL-6, TNF-α, CRP, NFL)
- Metabolic parameters: BMI, fasting glucose, insulin, HOMA-IR, lipid panel
- Motor complications (dyskinesia, motor fluctuations)
- Non-motor symptoms:
- PDQ-39
- SCOPA-AUT (autonomic dysfunction)
- MoCA (cognitive function)
- Epworth Sleepiness Scale
- Brain imaging:
- DAT-SPECT (dopaminergic transporter binding) at baseline and 12 months
- SWI (iron deposition) in substantia nigra
- Biomarkers:
- Gut microbiome composition (16S rRNA sequencing)
- Peripheral blood mononuclear cell (PBMC) mitochondrial function
- Autophagy markers in monocytes
- 80% power to detect 3.5-point difference in MDS-UPDRS III (α=0.05)
- Assuming 20% dropout
- Based on exenatide trial effect size (4.5 points)
- Intent-to-treat analysis
- Mixed-effects model for repeated measures
- Stratification by metabolic syndrome severity
- Corrections for multiple comparisons
¶ Risks and Mitigations
| Risk |
Mitigation |
| GI side effects (nausea, vomiting) |
Gradual titration, antiemetic as needed |
| Pancreatitis |
Exclusion of high-risk patients, lipase monitoring |
| Hypoglycemia |
Monitor fasting glucose, exclude intensive insulin users |
| Thyroid C-cell tumors |
Exclusion of patients with family history of medullary thyroid carcinoma |
- Personnel: $600,000
- Study drug/placebo: $400,000
- Lab assays: $300,000
- Imaging (DAT-SPECT, MRI): $400,000
- Patient compensation: $200,000
- Regulatory/IRB: $100,000
- Contingency (20%): $400,000
- Total: ~$2,400,000
| Milestone |
Timepoint |
| IRB submission |
Month 0 |
| IND application |
Month 2 |
| Recruitment start |
Month 6 |
| Last patient enrolled |
Month 18 |
| Last patient completed |
Month 30 |
| Primary analysis |
Month 34 |
- Primary: Statistically significant improvement in MDS-UPDRS III AND improvement in metabolic parameters
- Secondary: Reduction in neuroinflammatory markers, preservation of DAT binding
- Significance: Would provide evidence for metabolic modulation as disease-modifying therapy in PD
- Patients with vs without metabolic syndrome at baseline
- By number of metabolic syndrome components (2 vs 3+)
- By baseline HbA1c (prediabetic vs normal)
- By PD severity at baseline
To validate the hypothesis mechanistically:
- Peripheral: Measure mitochondrial function in patient-derived monocytes
- CSF: Assess autophagy markers (LC3, p62) and lysosomal function
- Imaging: Quantify brain insulin signaling via PET (if available)